ライフサイエンスコーパス: acute chest syndrome

1 alarial infections, vaso-occlusive pain, and acute chest syndrome.

2 e-dependent innate immune pathway to prevent acute chest syndrome.

3 ive crisis, a composite of painful crisis or acute chest syndrome.

4 ckle cell disease-related events, especially acute chest syndrome.

5 ies, or with severe or recurrent episodes of acute chest syndrome.

6 ssemia was admitted to the internal ward for acute chest syndrome.

7 equency of acute pain episodes or history of acute chest syndrome.

8 death, stroke, frequent pain, and recurrent acute chest syndrome.

9 ad frequent pain, and 3 (1.8%) had recurrent acute chest syndrome.

10 is area are current and uniquely relevant to acute chest syndrome.

11 rienced further episodes of pain, stroke, or acute chest syndrome.

12 hospitalized with mild to moderately severe acute chest syndrome.

13 requent pain (17 [24 percent]), or recurrent acute chest syndrome (10 [14 percent]).

14 aso-occlusive crises (mean [SD], 0.8 [2.4]), acute chest syndrome (109 of 3712 [2.9%]), and inpatient

15 %), acute splenic sequestration (19.1%), and acute chest syndrome (11.8%).

16 25.0%]), kidney disease (21 of 144 [14.6%]), acute chest syndrome (18 of 144 [12.5%]), and health car

17 patients) included ileus (5), bleeding (4), acute chest syndrome (5), pneumonia (2), portal vein thr

18 evels are associated with increased rates of acute chest syndrome (ACS) and pain.

19 ive Study of Sickle Cell Disease (CSSCD) for acute chest syndrome (ACS) and painful crisis.

20 ts with sickle cell disease hospitalized for acute chest syndrome (ACS) are at high risk of in situ p

21 GWAS of acute chest syndrome (ACS) detected a locus (rs79915189,

22 Pain and acute chest syndrome (ACS) episodes are 2 of the most co

23 Patients experienced 7.5 acute chest syndrome (ACS) events per 100 person-years,

24 Patients experienced 7.5 acute chest syndrome (ACS) events/100 person-years, comp

25 Acute chest syndrome (ACS) in patients with sickle cell

26 Acute chest syndrome (ACS) is a common, serious complica

27 Acute chest syndrome (ACS) is a leading cause of death i

28 The prevention and treatment of acute chest syndrome (ACS) is a major clinical concern i

29 Acute chest syndrome (ACS) is a major complication of si

30 Acute chest syndrome (ACS) is a significant cause of mor

31 Acute chest syndrome (ACS) is an important cause of morb

32 Acute chest syndrome (ACS) is associated with significan

33 Acute chest syndrome (ACS) is one of the leading acute s

34 Acute chest syndrome (ACS) is the leading cause of death

35 Acute chest syndrome (ACS) is the presence of a new pulm

36 Patients with severe acute chest syndrome (ACS) requiring endotracheal intuba

37 Acute chest syndrome (ACS) was the most common (35%) cau

38 Of these complications, acute chest syndrome (ACS), a form of acute lung injury,

39 e contributing factor for the development of Acute Chest Syndrome (ACS), a major cause of morbidity a

40 ications, including vaso-occlusive episodes, acute chest syndrome (ACS), pain, and stroke.

41 vasoactive mediator endothelin (ET-1) in the acute chest syndrome (ACS), we incubated bovine pulmonar

42 ed during sickle cell vasoocclusive pain and acute chest syndrome (ACS).

43 crises, a composite of painful crises and/or acute chest syndrome (ACS).

44 her than dactylitis, (2) dactylitis, and (3) acute chest syndrome (ACS).

45 e abnormal in children with a history of the acute chest syndrome (ACS).

46 Those with H1N1 influenza more often had acute chest syndrome (ACS; 34% vs 13%, P = .01) and requ

47 tted with sickle cell crisis, complicated by acute chest syndrome, acute respiratory distress syndrom

48 e substantially reduces episodes of pain and acute chest syndrome, admissions to hospital, and transf

49 left lung following exchange transfusion for acute chest syndrome and hyper-hemolytic syndrome.

50 generation of F2 isoprostanes, occurs during acute chest syndrome and may have an important role in t

51 stress may contribute to the pathogenesis of acute chest syndrome and measured F2 isoprostanes, a non

52 usion for prevention of stroke, treatment of acute chest syndrome and perioperative transfusion manag

53 ions of SCD are of particular importance, as acute chest syndrome and pulmonary hypertension have the

54 sickle cell disease, as well as a link with acute chest syndrome and vaso-occlusive crisis.

55 Mortality, HbF levels, painful episodes, acute chest syndrome, and blood cell counts.

56 y repeated episodes of severe acute pain and acute chest syndrome, and by other complications includi

57 ses significantly, decrease the incidence of acute chest syndrome, and decrease the need for blood tr

58 centration and rate of and recent episode of acute chest syndrome, and elevated systolic blood pressu

59 velocity, white blood cell count, history of acute chest syndrome, and hemoglobin levels, demonstrate

60 and recurrent episodes of pain, dactylitis, acute chest syndrome, and hospitalization; even infants

61 splenic sequestration, or priapism) and the acute chest syndrome, and patient-reported outcomes were

62 ion associated with increased rates of pain, acute chest syndrome, and premature death in human sickl

63 bF, lowers rates of pain crisis, episodes of acute chest syndrome, and requirements for blood transfu

64 such as acute respiratory distress syndrome, acute chest syndrome, and sepsis.

65 as acute anemia, vaso-occlusive crises, and acute chest syndrome; and/or from pregnancy-related comp

66 ome, the etiological mechanisms that trigger acute chest syndrome are largely unknown.Objectives: To

67 cute exacerbation of asthma or an episode of acute chest syndrome are two distinct entities that need

68 increase in F2 isoprostanes in patients with acute chest syndrome as compared with normal volunteers.

69 t pulmonary manifestations of SCD, including acute chest syndrome, asthma, and pulmonary hypertension

70 cell disease include airway hyperreactivity, acute chest syndrome, chronic sickle lung disease, pulmo

71 Acute chest syndrome describes new respiratory symptoms

72 Individuals who had acute chest syndrome during the trial had 32% mortality

73 Risk factors for asthma exacerbation and an acute chest syndrome episode are similar, and both can p

74 usive pain crises per year (n = 12), or >/=2 acute chest syndrome episodes (n = 4) in the 2 years pre

75 , children with sickle cell disease who have acute chest syndrome episodes have worse pulmonary funct

76 sed incidence of vaso-occlusive pain events, acute chest syndrome episodes, and earlier death.

77 function than those who have not experienced acute chest syndrome episodes.

78 cy and severity of vaso-occlusive crises and acute chest syndrome episodes.

79 episodes (0.60; 95% CI 0.52-0.70; p<0.0001), acute chest syndrome events (0.21; 0.13-0.33; p<0.0001),

80 of eight patients transplanted for recurrent acute chest syndrome had stable pulmonary function.

81 ted crises (defined as crises other than the acute chest syndrome, hepatic sequestration, splenic seq

82 p<0.0001), with some evidence for decreased acute chest syndrome, hospitalisation rates, and transfu

83 t period, but significant benefits for pain, acute chest syndrome, hospitalizations, and transfusions

84 enter study, we analyzed 671 episodes of the acute chest syndrome in 538 patients with sickle cell di

85 eal life support could be helpful for severe acute chest syndrome in adults sickle cell disease, beca

86 corporeal life support experience for severe acute chest syndrome in four referral centers in France.

87 thods: TASC (Therapeutic Anticoagulation for Acute Chest Syndrome in Sickle Cell Disease) is a random

88 roved pulmonary hypertension associated with acute chest syndrome in sickle cell disease, and several

89 have been implicated in the pathogenesis of acute chest syndrome in subjects with sickle cell anemia

90 ammatory state" that predisposes patients to acute chest syndrome in the setting of triggering factor

91 02; 95% CI 1.00-1.003; P = .015), and higher acute chest syndrome incidence rate (HR per event/year 1

92 uired extracorporeal life support for severe acute chest syndrome, including 10 (45%) veno-venous and

93 by hemolytic anemia, acute and chronic pain, acute chest syndrome; increased incidence of stroke, nep

94 Acute chest syndrome is a frequent cause of acute lung d

95 Among patients with sickle cell disease, the acute chest syndrome is commonly precipitated by fat emb

96 The acute chest syndrome is the leading cause of death among

97 Acute lung injury, referred to as the acute chest syndrome, is a major cause of morbidity and

98 Among patients with a history of acute chest syndrome, lung function stabilized; among pa

99 udy was ICU survival of patients with severe acute chest syndrome managed with extracorporeal life su

100 ious complications and organ damage, such as acute chest syndrome, multiorgan failure, and sudden dea

101 uded a history of stroke (n = 12), recurrent acute chest syndrome (n = 5), and recurrent painful cris

102 10 (91%) of 11 serious adverse events were acute chest syndrome (nine in the no-preoperative-transf

103 atients during vaso-occlusive crisis and the acute chest syndrome, nitric oxide is destroyed by incre

104 The pulmonary findings of acute chest syndrome of sickle cell disease have been we

105 itric oxide metabolism is altered during the acute chest syndrome of sickle cell disease.

106 ratio, 0.43; 95% CI, 0.34 to 0.56), cases of acute chest syndrome or pneumonia (incidence rate ratio,

107 of hypoperfusion/hypoxia, as observed during acute chest syndromes or acute anemic events (AAE), and

108 oke syndromes) or remote organ injury (e.g., acute chest syndrome) or the systematization of inflamma

109 evious stroke, and presence of hypertension, acute chest syndrome, or diabetes.

110 ity compared with 18% of individuals without acute chest syndrome (P =.02).

111 een patients with sickle cell disease during acute chest syndrome (pre- and postexchange transfusion)

112 Acute chest syndrome-related and all-cause 7- and 30-day

113 (vaso-occlusive painful crisis, dactylitis, acute chest syndrome, splenic sequestration, or blood tr

114 Symptoms include chronic anemia, acute chest syndrome, stroke, splenic and renal dysfunct

115 known to occur in the lung and contribute to acute chest syndrome, the etiological mechanisms that tr

116 When the acute chest syndrome was diagnosed, patients had hypoxia

117 A specific cause of the acute chest syndrome was identified in 38 percent of all

118 ute respiratory distress syndrome, including acute chest syndrome, were 56 of 3144 deliveries (1.8%)